Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!
Amit Kumar, insider at Anixa Biosciences
Amit Kumar Insider Alerts

Get notified the next time Amit Kumar buys or sells Anixa Biosciences stock. Enter your email address below to get our daily insider buying and selling report.

Amit Kumar Insider Information

Dr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners, and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002-2008. Dr. Kumar is currently Chairman, President and CEO of Anixa Biosciences and he sits on the Board of other public and private companies. He has served on the Board of the American Cancer Society since 2016. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a post-doctoral fellowship at Harvard.

What is Amit Kumar's net worth?

The estimated net worth of Amit Kumar is at least $946,080.00 as of July 23rd, 2021. Dr. Kumar owns 292,000 shares of Anixa Biosciences stock worth more than $946,080 as of January 20th. This net worth approximation does not reflect any other investments that Dr. Kumar may own. Learn More.

What is Amit Kumar's salary?

As the CEO of Anixa Biosciences, Inc., Dr. Kumar earned a total compensation package of $2,395,265.00 in 2020. Dr. Kumar earned a salary of $521,625.00, a bonus of $160,000.00, options awards of $1,674,400.00, and other compensation of $39,240.00.

How do I contact Amit Kumar?

The corporate mailing address for Dr. Kumar and other Anixa Biosciences executives is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. Anixa Biosciences can also be reached via phone at (408) 708-9808 and via email at [email protected]

Has Amit Kumar been buying or selling shares of Anixa Biosciences?

Within the last three months, Amit Kumar has bought $60,000.00 in shares of Anixa Biosciences stock. Most recently, on Friday, January 7th, Amit Kumar bought 20,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.00 per share, with a total value of $60,000.00.

Who are Anixa Biosciences' active insiders?

Anixa Biosciences' insider roster includes Arnold Baskies (Director), Emily Gottschalk (Director), Amit Kumar (CEO), and Lewis Titterton, Jr. (Director).

Are insiders buying or selling shares of Anixa Biosciences?

In the last year, Anixa Biosciences insiders bought shares 15 times. They purchased a total of 180,544 shares worth more than $728,457.44. The most recent insider tranaction occured on January, 11th when Director Lewis H Titterton Jr bought 2,000 shares worth more than $6,400.00. Insiders at Anixa Biosciences own 19.8 % of the company.

Information on this page was last updated on 1/11/2022.

Amit Kumar Insider Trading History at Anixa Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/7/2022Buy20,000$3.00$60,000.00View SEC Filing Icon  
10/29/2021Buy2,000$4.77$9,540.00View SEC Filing Icon  
7/23/2021Buy5,000$4.28$21,400.00292,000View SEC Filing Icon  
3/25/2021Buy5,000$4.86$24,300.00277,000View SEC Filing Icon  
1/29/2021Buy10,000$3.73$37,300.00272,000View SEC Filing Icon  
9/11/2020Buy28,000$2.11$59,080.00262,000View SEC Filing Icon  
6/12/2020Buy20,000$2.03$40,600.00234,000View SEC Filing Icon  
1/14/2020Buy20,000$2.99$59,800.00194,000View SEC Filing Icon  
4/26/2019Buy4,000$4.21$16,840.00View SEC Filing Icon  
4/24/2019Buy10,000$4.27$42,700.00View SEC Filing Icon  
10/25/2018Buy11,000$3.90$42,900.00View SEC Filing Icon  
See Full Table

Amit Kumar Buying and Selling Activity at Anixa Biosciences

This chart shows Amit Kumar's buying and selling at Anixa Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anixa Biosciences Company Overview

Anixa Biosciences logo
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
Read More

Today's Range

Now: $3.24
Low: $3.15
High: $3.37

50 Day Range

MA: $3.44
Low: $2.78
High: $4.70

2 Week Range

Now: $3.24
Low: $2.71
High: $8.09


87,310 shs

Average Volume

129,837 shs

Market Capitalization

$97.63 million

P/E Ratio


Dividend Yield



Say Goodbye to Your Smartphone
According to Microsoft engineer Alex Kipman, “Smartphones are yesterday's news. The phone is already dead. People just haven't realized.”

And it’s all thanks to the device inside this black box…
Click here to see it in action.